Product Development Meeting

from the beginning

Become A Social Innovator

• Presentation / Q&A

• Agenda

• Forward‐looking Statements

1. Santen's Product Development

Presenter：

Shigeo Taniuchi　President & Chief Executive Officer

• CORE PRINCIPLE and WORLD VISION

• MTP2025‐Santen 2030

• A Path Towards Santen 2030 “Social Innovator

• Product Development in MTP2025: Focus on Core Business Areas Including Life Cycle Managements

• Product Development in MTP2025: Challenges to New Areas for Santen 2030

• R&D Productivity Formula

• Efficient Product Development

2. Enrich Pipeline based on Patient's Needs

Presenter：

Reza Haque, MD, Ph.D.　Head of Ophthalmology Innovation Center

• Mission for Ophthalmology Innovation Center

• 1) People

• 2) Disease Strategy‐1

• 2) Disease Strategy‐2

• 2) Disease Strategy: New Frontier (Myopia)‐1

• 2) Disease Strategy: New Frontier (Myopia)‐2

• 2) Disease Strategy: New Frontier (Myopia)‐3

• 2) Disease Strategy: New Frontier (Presbyopia)‐1

• 2) Disease Strategy: New Frontier (Presbyopia)‐2

• 2) Disease Strategy: New Frontier (Presbyopia)‐3

• 2)Disease Strategy: Core Business (Dry eye)

• 2) Disease Strategy: Core Business (Glaucoma)

• 3) Network‐1

• 3) Network‐2

• Leadership

3. Pursue Added Value by Steadily Promoting Product Development

Presenter：

Peter Sallstig, MD, MBA　Corporate Officer, Head of Product Development Division

• Mission for Product Development Division

• 1) Development Strategy

• 1) Development Strategy (Myopia)‐1

• 1) Development Strategy (Myopia)‐2

• 1) Development Strategy (Myopia)‐3

• 1) Development Strategy (Myopia)‐4

• 1) Development Strategy

• 1) Development Strategy (Ptosis)‐1

• 1) Development Strategy (Ptosis)‐2

• 1) Development Strategy (Retinitis Pigmentosa)‐1

• 1) Development Strategy (Retinitis Pigmentosa)‐2

• 1) Development Strategy (Retinitis Pigmentosa)‐3

• 2) Maximized Product Value-1

• 2) Maximized Product Value‐2

• 2) Maximized Product Value (Dry Eye)

• 2) Maximized Product Value (Dry-Eye)

• 2) Maximized Product Value

• 3) Global Operation Excellence

• 3) Global Operation Excellence: US Development

• 3) Global Operation Excellence: China R&D

• Leadership

4. Improve Portfolio Value through Industrialization and Commercialization

Presenter：

Hiroki Sakai, Ph.D.　General Manager,Portfolio Strategy & Global Marketing Group, Corporate Development Division

• Direction of Global Myopia Business Expansion

• Building the Ecosystem for Myopia

• Manufacturing and Supply Chain System that can Meet Global Demand

• Treatment Myopia Patient Potential in China

• Classification of Ptosis Market Opportunities

• Blepharoptosis Market Opportunity Classification by Age

• Business Opportunity of STN1013800

• Potential in Santen's Major Regions

5. Summary

Presenter：

Shigeo Taniuchi　President & Chief Executive Officer

• Efficient Product Development

• Long-term Growth through MTP2025 and Santen 2030

Appendix

• Short-term Event Schedule in Research & Development

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7